Neuren Pharmaceuticals Ltd
ASX:NEU
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.72
22.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
NEU
stock under the Base Case scenario is
hidden
AUD.
Compared to the current market price of 18.17 AUD,
Neuren Pharmaceuticals Ltd
is
hidden
.
Valuation History
Neuren Pharmaceuticals Ltd
NEU looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether NEU usually does or if today's premium is unusual.
Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Neuren Pharmaceuticals Ltd.
Fundamental Analysis
NEU Profitability Score
Profitability Due Diligence
Score
NEU Solvency Score
Solvency Due Diligence
Score
Select up to 3 indicators:
Select up to 3 indicators:
Regulatory uncertainty surrounding Neuren’s lead candidate trofinetide—particularly in complex neurological indications—poses a significant risk, as any delays in approvals or unfavorable trial data could derail the company’s revenue timeline and shake investor confidence.
Trofinetide’s potential first-mover advantage in Rett syndrome offers a pathway to regulatory approval and commercial success, creating a strong, near-term revenue stream if upcoming data and launches proceed favorably.
Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Ltd
Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Neuren Pharmaceuticals Ltd
Wall St
Price Targets
NEU Price Targets Summary
Neuren Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
NEU
is 25.46 AUD
with a low forecast of 21.41 AUD and a high forecast of 32.03 AUD.
Dividends
Current shareholder yield for
NEU is
hidden
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NEU
stock under the Base Case scenario is
hidden
AUD.
Compared to the current market price of 18.17 AUD,
Neuren Pharmaceuticals Ltd
is
hidden
.